Terms: = Endocrine gland cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
19 results:
1. A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer.
Zong S; Xu PP; Xu YH; Guo Y
J Ovarian Res; 2022 Aug; 15(1):90. PubMed ID: 35915456
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of clinical outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract] [Full Text] [Related]
3. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on clinical Behavior of Medullary Thyroid Carcinoma.
Mishra V; Kowtal P; Rane P; Sarin R
Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
[TBL] [Abstract] [Full Text] [Related]
4. Expression of ACAP1 Is Associated with Tumor Immune Infiltration and clinical outcome of Ovarian cancer.
Zhang J; Zhang Q; Zhang J; Wang Q
DNA Cell Biol; 2020 Sep; 39(9):1545-1557. PubMed ID: 32456571
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.
Necchi A; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Ross JS; Jacob JM
Eur Urol Focus; 2019 Sep; 5(5):748-755. PubMed ID: 31147264
[TBL] [Abstract] [Full Text] [Related]
6. Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma.
Al-Zoughbi W; Schauer S; Pichler M; Hoefler G
Pathobiology; 2018; 85(5-6):342-347. PubMed ID: 30227407
[TBL] [Abstract] [Full Text] [Related]
7. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
[TBL] [Abstract] [Full Text] [Related]
8. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
[TBL] [Abstract] [Full Text] [Related]
9. In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.
Ocaña A; Pérez-Peña J; Alcaraz-Sanabria A; Sánchez-Corrales V; Nieto-Jiménez C; Templeton AJ; Seruga B; Pandiella A; Amir E
Oncotarget; 2016 Apr; 7(16):22865-72. PubMed ID: 26992217
[TBL] [Abstract] [Full Text] [Related]
10. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.
Togami S; Sasajima Y; Kasamatsu T; Oda-Otomo R; Okada S; Ishikawa M; Ikeda S; Kato T; Tsuda H
Pathol Oncol Res; 2015 Apr; 21(2):487-94. PubMed ID: 25370301
[TBL] [Abstract] [Full Text] [Related]
11. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
[TBL] [Abstract] [Full Text] [Related]
12. KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.
Heublein S; Grasse K; Hessel H; Burges A; Lenhard M; Engel J; Kirchner T; Jeschke U; Mayr D
BMC Cancer; 2013 Oct; 13():483. PubMed ID: 24139521
[TBL] [Abstract] [Full Text] [Related]
13. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma.
Evans JJ; Crist HS; Durvesh S; Bruggeman RD; Goldenberg D
Cancer Biol Ther; 2012 Jul; 13(9):776-81. PubMed ID: 22688732
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells.
Mern DS; Hasskarl J; Burwinkel B
Br J Cancer; 2010 Oct; 103(8):1237-44. PubMed ID: 20842131
[TBL] [Abstract] [Full Text] [Related]
15. Expression of p16(ink4a) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Chang DT; Chapman CH; Norton JA; Visser B; Fisher GA; Kunz P; Ford JM; Koong AC; Pai RK
Cancer; 2010 Nov; 116(22):5179-87. PubMed ID: 20665497
[TBL] [Abstract] [Full Text] [Related]
16. High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.
Wolf AM; Rumpold H; Reimer D; Marth C; Zeimet AG; Wolf D
Gynecol Oncol; 2010 Sep; 118(3):244-50. PubMed ID: 20603238
[TBL] [Abstract] [Full Text] [Related]
17. The status of cdkn2a alpha (p16ink4a) and beta (p14arf) transcripts in thyroid tumour progression.
Ferru A; Fromont G; Gibelin H; Guilhot J; Savagner F; Tourani JM; Kraimps JL; Larsen CJ; Karayan-Tapon L
Br J Cancer; 2006 Dec; 95(12):1670-7. PubMed ID: 17117177
[TBL] [Abstract] [Full Text] [Related]
18. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract] [Full Text] [Related]
19. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer.
Kusume T; Tsuda H; Kawabata M; Inoue T; Umesaki N; Suzuki T; Yamamoto K
Clin Cancer Res; 1999 Dec; 5(12):4152-7. PubMed ID: 10632354
[TBL] [Abstract] [Full Text] [Related]
